Published August 2017 | Version v1
Journal article

Profile of European proton and carbon ion therapy centers assessed by the EORTC facility questionnaire

  • 1. RTQA Strategic Committee, EORTC, Brussels (Belgium)
  • 2. Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, Villigen (Switzerland)
  • 3. EORTC HQ, Brussels (Belgium)
  • 4. Eye Proton therapy Centre Clatterbridge Cancer Centre, Bebington (United Kingdom)
  • 5. Protontherapy Center (ICPO), Institut Curie, Paris (France)
  • 6. Clinic for Particle Therapy, West German Proton Therapy Centre Essen, University Hospital Essen (Germany)
  • 7. Rinecker Proton Therapy Center, Munich (Germany)
  • 8. Skandionklinick, Uppsala (Sweden)
  • 9. Charité-Universitätsmedizin Berlin, BerlinProtonen am HZB (Germany)
  • 10. University Hospital of Heidelberg (Germany)
  • 11. University of Heidelberg (Germany)
  • 12. Proton Therapy Centre, Azienda Provinciale per i Servizi Sanitari, Trento (Italy)
  • 13. Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden (Germany)
  • 14. Scientific Directorate, European Institute of Oncology, Centro Nazionale Adroterapia Oncologica, Milan and Pavia (Italy)
  • 15. Proton Therapy Center, Prague (Czech Republic)

Description

Background: We performed a survey using the modified EORTC Facility questionnaire (pFQ) to evaluate the human, technical and organizational resources of particle centers in Europe. Material and methods: The modified pFQ consisted of 235 questions distributed in 11 sections accessible on line on an EORTC server. Fifteen centers from 8 countries completed the pFQ between May 2015 and December 2015. Results: The average number of patients treated per year and per particle center was 221 (range, 40–557). The majority (66.7%) of centers had pencil beam or raster scanning capability. Four (27%) centers were dedicated to eye treatment only. An increase in the patients-health professional FTE ratio was observed for eye tumor only centers when compared to other centers. All centers treated routinely chordomas/chondrosarcomas, brain tumors and sarcomas but rarely breast cancer. The majority of centers treated pediatric cases with particles. Only a minority of the queried institutions treated non-static targets. Conclusions: As the number of particle centers coming online will increase, the experience with this treatment modality will rise in Europe. Children can currently be treated in these facilities in a majority of cases. The majority of these centers provide state of the art particle beam therapy.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.radonc.2017.07.012

Additional details

Identifiers

DOI
10.1016/j.radonc.2017.07.012;
PII
S0167-8140(17)32471-4;

Publishing Information

Journal Title
Radiotherapy and Oncology
Journal Volume
124
Journal Issue
2
Journal Page Range
p. 185-189
ISSN
0167-8140
CODEN
RAONDT

INIS

Country of Publication
Ireland
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
49072511
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CARBON IONS; MAMMARY GLANDS; NEOPLASMS; PROTON BEAMS; RADIOTHERAPY; SKELETAL DISEASES
Descriptors DEC
BEAMS; BODY; CHARGED PARTICLES; DISEASES; GLANDS; IONS; MEDICINE; NUCLEAR MEDICINE; NUCLEON BEAMS; ORGANS; PARTICLE BEAMS; RADIOLOGY; THERAPY

Optional Information

Copyright
Copyright (c) 2017 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.